Evommune, Inc. presented late-breaking Phase 2a proof-of-concept data for EVO301 in atopic dermatitis at the European Academy of Dermatology and Venereology Congress on October 1, 2026. The trial met its primary endpoint with a 55% least-squares mean reduction in EASI scores versus 22% for placebo (p<0.01) at Week 12. Biomarker analyses confirmed robust Th2 pathway modulation and broad anti-inflammatory activity across Th1, Th17/22 pathways. The company plans to initiate a subcutaneous Phase 2b dose-ranging trial in mid-2027. Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases.
